Literature DB >> 9805131

Implications of a novel cryptic splice site in the BRCA1 gene.

J D Hoffman1, S E Hallam, V L Venne, E Lyon, K Ward.   

Abstract

This study was designed to determine the significance of a single intronic base change (IVS5-12 G-->A) found in a family with a history of breast cancer. This change is predicted to form a cryptic splice site resulting in the addition of 11 nucleotides to the BRCA1 transcript. The BRCA1 gene of the relatives and control individuals was sequenced and analyzed using RT-PCR, ASO hybridization, and size fractionation. All patients showed an 11 nucleotide insert at the intron 5/exon 6 boundary. This variant is likely to form a short protein product incapable of the hypothesized tumor suppressor functions of the BRCA1 gene. This information is important for providing counseling for families with this cryptic splice site and a family history of breast cancer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9805131

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  11 in total

1.  Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort.

Authors:  Elisabeth Jarhelle; Hilde Monica Frostad Riise Stensland; Lovise Mæhle; Marijke Van Ghelue
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

2.  Splicing and multifactorial analysis of intronic BRCA1 and BRCA2 sequence variants identifies clinically significant splicing aberrations up to 12 nucleotides from the intron/exon boundary.

Authors:  Phillip J Whiley; Lucia Guidugli; Logan C Walker; Sue Healey; Bryony A Thompson; Sunil R Lakhani; Leonard M Da Silva; Sean V Tavtigian; David E Goldgar; Melissa A Brown; Fergus J Couch; Amanda B Spurdle
Journal:  Hum Mutat       Date:  2011-04-12       Impact factor: 4.878

Review 3.  Alternative splicing and disease.

Authors:  Jamal Tazi; Nadia Bakkour; Stefan Stamm
Journal:  Biochim Biophys Acta       Date:  2008-10-17

4.  Germline truncating-mutations in BRCA1 and MSH6 in a patient with early onset endometrial cancer.

Authors:  Karin Kast; Teresa M Neuhann; Heike Görgens; Kerstin Becker; Katja Keller; Barbara Klink; Daniela Aust; Wolfgang Distler; Evelin Schröck; Hans K Schackert
Journal:  BMC Cancer       Date:  2012-11-20       Impact factor: 4.430

5.  Biased exon/intron distribution of cryptic and de novo 3' splice sites.

Authors:  Jana Královicová; Mikkel B Christensen; Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2005-09-01       Impact factor: 16.971

6.  Adding In Silico Assessment of Potential Splice Aberration to the Integrated Evaluation of BRCA Gene Unclassified Variants.

Authors:  Maxime P Vallée; Tonya L Di Sera; David A Nix; Andrew M Paquette; Michael T Parsons; Russel Bell; Andrea Hoffman; Frans B L Hogervorst; David E Goldgar; Amanda B Spurdle; Sean V Tavtigian
Journal:  Hum Mutat       Date:  2016-04-15       Impact factor: 4.878

7.  Tissue Restricted Splice Junctions Originate Not Only from Tissue-Specific Gene Loci, but Gene Loci with a Broad Pattern of Expression.

Authors:  Matthew S Hestand; Zheng Zeng; Stephen J Coleman; Jinze Liu; James N MacLeod
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

8.  Differentially expressed alternatively spliced genes in malignant pleural mesothelioma identified using massively parallel transcriptome sequencing.

Authors:  Lingsheng Dong; Roderick V Jensen; Assunta De Rienzo; Gavin J Gordon; Yanlong Xu; David J Sugarbaker; Raphael Bueno
Journal:  BMC Med Genet       Date:  2009-12-31       Impact factor: 2.103

9.  Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.

Authors:  Eva Machackova; Lenka Foretova; Mirka Lukesova; Petra Vasickova; Marie Navratilova; Ilse Coene; Hana Pavlu; Veronika Kosinova; Jitka Kuklova; Kathleen Claes
Journal:  BMC Cancer       Date:  2008-05-20       Impact factor: 4.430

Review 10.  MicroRNA and Alternative mRNA Splicing Events in Cancer Drug Response/Resistance: Potent Therapeutic Targets.

Authors:  Rahaba Marima; Flavia Zita Francies; Rodney Hull; Thulo Molefi; Meryl Oyomno; Richard Khanyile; Sikhumbuzo Mbatha; Mzubanzi Mabongo; David Owen Bates; Zodwa Dlamini
Journal:  Biomedicines       Date:  2021-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.